My Pick of the Most Important Study from the European Society of Cardiology Meeting
Sensible Medicine
SEPTEMBER 4, 2023
The newer DOAC drugs have been compared to VKAs (warfarin or warfarin-like) in multiple trials with over 50K patients. This, plus convenience—no INR testing—has led to DOAC dominance of the market. The average age of patients in these trials was in the low 70s, and few were considered frail. And that is THE issue.
98 
Let's personalize your content